Tempus Launches ArteraAI Prostate Test for Metastatic Patients
Tempus AI, Inc. has launched the ArteraAI Prostate Test, the first digital pathology algorithm for prostate cancer available for clinical use within its ecosystem. This CLIA-certified and CAP-accredited prognostic test aims to assist urologists and oncologists in personalizing therapy intensity for patients with metastatic hormone-sensitive prostate cancer.
CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic test will be fully integrated into the Tempus platform, providing urologists and oncologists with a digital pathology solution that helps inform personalization of therapy intensity in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The ArteraAI Prosta
